RTP Mobile Logo
Visiting Professors: Hematologic Oncology Edition, Issue 1, 2011
Released December 2011

Featuring clinical investigator Dr Mitchell R Smith’s perspective on his time spent visiting patients with non-Hodgkin lymphomas and chronic lymphocytic leukemia in the clinic of community oncologist Dr Lyle Feinstein. (Audio Content)

CE Disclosures and Faculty Information

  • OVERVIEW OF ACTIVITY

    Non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL) comprise a heterogeneous group of lymphoproliferative disorders and belong to one of the most rapidly evolving fields in hematology and oncology. Published results from ongoing clinical trials lead to the continual emergence of new therapeutic agents and changes in the use of existing treatments. Individualized treatment decisions are driven by disease-specific and patient-specific characteristics. In order to offer optimal patient care — including the option of clinical trial participation — practicing medical oncologists and hematologists must be well informed of these advances. To provide clinicians with therapeutic strategies to address the disparate needs of patients with NHL or CLL, the Visiting Professors audio series employs an innovative case-based approach that unites the perspectives of leading NHL/CLL investigators and community oncologists as they explore the intricacies of making treatment decisions. Upon completion of this CME activity, medical oncologists and hematologists should be able to formulate an up-to-date and more complete approach to the care of patients with NHL or CLL.

    LEARNING OBJECTIVES

    • Use case-based learning, innovative communication strategies and shared clinical insight to provide comprehensive and compassionate oncology care.
    • Use prognostic and predictive clinical and molecular markers to aid in treatment decision-making for NHL and CLL.
    • Refine current treatment approaches through appraisal of therapeutic advances in NHL and CLL.
    • Communicate the existing and emerging therapeutic roles of proteasome inhibitors and IMiDs to patients with NHL.
    • Develop an algorithm for the risk-stratified and age-appropriate induction treatment of mantle-cell lymphoma (MCL).
    • Recall the rationale for and design of clinical trials investigating proteasome inhibitors as part of initial therapy for MCL.
    • Counsel appropriately selected patients about the availability of ongoing clinical trial participation.

    ACCREDITATION STATEMENT

    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CME credit is no longer available for this issue

    CREDIT DESIGNATION STATEMENT

    CME credit is no longer available for this issue

    HOW TO USE THIS CME ACTIVITY

    CME credit is no longer available for this issue

    This CME activity contains an audio component. The participant should listen to the audio MP3s.

    CONTENT VALIDATION AND DISCLOSURES

    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTYDr Feinstein had no real or apparent conflicts of interest to disclose. The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process: Dr SmithAdvisory Committee: Pfizer Inc; Speakers Bureau: Allos Therapeutics, Cephalon Inc, Genentech BioOncology, Millennium: The Takeda Oncology Company, Spectrum Pharmaceuticals Inc.

    MODERATORDr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: Abbott Laboratories, Allos Therapeutics, Amgen Inc, Astellas Pharma Global Development Inc, Bayer HealthCare Pharmaceuticals/Onyx Pharmaceuticals Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Cephalon Inc, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, EMD Serono Inc, Genentech BioOncology, Genomic Health Inc, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Lilly USA LLC, Medivation Inc, Millennium: The Takeda Oncology Company, Mundipharma International Limited, Novartis Pharmaceuticals Corporation, Sanofi, Seattle Genetics and Teva Pharmaceuticals.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from Celgene Corporation and Genentech BioOncology/Biogen Idec.

    Hardware/Software Requirements:
    An Internet connection that is at least 28.8 Kbps
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 6.x or newer, Firefox 2.x or newer, or Safari 2.x or newer
    Macromedia Flash plug-in 6.0 or greater
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date: December 2011
    Expiration date: December 2012

Acknowledge and close

Listen to audio:
CLINICAL INVESTIGATOR
Mitchell R Smith, MD, PhD
Director, Lymphoma Service
Fox Chase Cancer Center
Philadelphia, Pennsylvania

CONSULTING ONCOLOGIST
Lyle Feinstein, MD
Director, Bone Marrow
Transplant Program
Memorial Cancer Institute
Memorial Healthcare System
Pembroke Pines, Florida
Visiting Professors: Hematologic Oncology Edition, Issue 1, 2011
Released December 2011

Featuring clinical investigator Dr Mitchell R Smith’s perspective on his time spent visiting patients with non-Hodgkin lymphomas and chronic lymphocytic leukemia in the clinic of community oncologist Dr Lyle Feinstein. (Audio Content)

Read print: